| Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas (NCT04933617) | National Cancer Institute (NCI) | 2022-03-24 |
| Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy (NCT05075603) | NeoImmuneTech | 2021-07-29 |
| A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL) (NCT04914741) | Peter MacCallum Cancer Centre, Australia | 2021-06-29 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (NCT04855253) | Masonic Cancer Center, University of Minnesota | 2021-06-09 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL (NCT04796857) | Huiqiang Huang | 2021-03-31 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients (NCT04858568) | University Hospital Southampton NHS Foundation Trust | 2021-03-11 |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (NCT04836507) | Curocell Inc. | 2021-03-02 |
| RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (NCT04844086) | Eden BioCell Ltd. | 2021-03-02 |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma (NCT04594642) | AstraZeneca | 2021-03-02 |
| Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma (NCT04257578) | University of Washington | 2020-12-02 |
| Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity (NCT04503538) | Wake Forest University Health Sciences | 2020-12-01 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL (NCT04555811) | Masonic Cancer Center, University of Minnesota | 2020-09-22 |
| DLBCL Interim Response Evaluation for Customised Therapy (NCT04226937) | Cambridge University Hospitals NHS Foundation Trust | 2020-09-17 |
| Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Lymphoma (NCT04479267) | Barbara Ann Karmanos Cancer Institute | 2020-08-21 |
| Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL) (NCT04542824) | Genmab | 2020-08-20 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (NCT04476459) | Huiqiang Huang | 2020-07-23 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma (NCT04058470) | Huiqiang Huang | 2020-04-24 |
| Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma (NCT04205838) | Jonsson Comprehensive Cancer Center | 2020-03-04 |
| Study of CAR-T Therapy in Older Patients (NCT04300998) | Memorial Sloan Kettering Cancer Center | 2020-03-04 |
| Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma (NCT03995147) | University of Chicago | 2019-08-29 |
| DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma (NCT03837873) | Institute of Hematology & Blood Diseases Hospital, China | 2019-01-21 |
| Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma (NCT03656835) | Ohio State University Comprehensive Cancer Center | 2018-09-26 |
| DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (NCT03620578) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-08-01 |
| Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma (NCT04067414) | Institute of Hematology & Blood Diseases Hospital, China | 2018-06-08 |
| A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6 (NCT03255096) | Hoffmann-La Roche | 2017-08-28 |
| Cyclophosphamide and Alemtuzumab In Lymphoma (NCT03132584) | Dana-Farber Cancer Institute | 2017-07-30 |
| Study of Venetoclax Plus DA-EPOCH-R for the Treatment of Aggressive B-Cell Lymphomas (NCT03036904) | Weill Medical College of Cornell University | 2017-02-06 |
| Brentuximab Vedotin, Bendamustine, and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT02623920) | University of Arizona | 2015-12-16 |
| Treatment for Advanced B-Cell Lymphoma (NCT01859819) | New York Medical College | 2013-01-01 |